Associated Genetic Biomarkers
NTRK1 F589L is present in 0.01% of AACR GENIE cases, with gallbladder carcinoma having the greatest prevalence .
NTRK1 F589L is a predictive biomarker for use of larotrectinib in patients.
Of the therapies with NTRK1 F589L as a predictive biomarker, 1 is FDA-approved in at least one clinical setting.
Malignant solid tumor has the most therapies targeted against NTRK1 F589L or its related pathways .
Malignant Solid Tumor -
|Biomarker Criteria:||Predicted Response: Acquired Resistance|
|Clinical Setting(s): Metastatic (FDA, MCG)|
|Note: Secondary mutations in the NTRK genes confer resistance to larotrectinib.|
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.